Abstract: Zinc or copper (II) salt which can be used as a biocide, having the general formula CH2C(R1)CO—M—OCOR2(OH)m(COOH)n wherein M is Zn or Cu, R1 is selected from the group comprising hydrogen and methyl, R2 is substituted C1-C5 alkyl, m=0-5, n=0-2, m+n=1-5.

Abstract: The invention relates to a process for transvinylation of a carboxylic acid feedstock with a vinyl ester feedstock to obtain a vinyl ester product and the corresponding acid of the vinyl ester feedstock in the presence of one or more ruthenium catalysts, wherein a) the vinyl ester feedstock, the carboxylic acid feedstock and a ruthenium catalyst are fed to the reactor, and b) the transvinylation reaction is carried out, characterized in that a carbonyl-free Ru(III) carboxylate is used as the ruthenium catalyst and in that no carbon monoxide is supplied, c) the reaction is carried out at a temperature of 110 to 170° C., d) upon completion of the transvinylation reaction, the vinyl ester feedstock and the corresponding acid are separated from the reaction mixture by distillation, e) the vinyl ester product is separated by distillation from the bottom product of the distillation, and f) the remaining reaction mixture is recycled into the reactor.

Abstract: The invention relates to a process to prepare complex oligomeric structures obtained from vegetable oils. The process allows to use a mixture of triglycerides containing dicarboxylic acids produced by the oxidative cleavage of vegetable oils as a starting material, these oils being subjected to a step of heating (condensation) followed by a step of esterification with alcohols at temperatures up to 250° C.

Abstract: In an embodiment, a method of producing a carbonate comprises reacting carbon monoxide and chlorine in a phosgene reactor in the presence of a catalyst to produce a first product comprising phosgene; wherein carbon tetrachloride is present in the first product in an amount of 0 to 10 ppm by volume based on the total volume of phosgene; and reacting a monohydroxy compound with the phosgene to produce the carbonate; wherein the phosgene reactor comprises a tube, a shell, and a space located between the tube and the shell; wherein the tube comprises one or more of a mini-tube section and a second tube section; a first concentric tube concentrically located in the shell; a twisted tube; an internal scaffold; and an external scaffold.

Abstract: A curable sensitizer that exhibits a radical-polymerization sensitizing ability that conventional sensitizers do not have in a polymerization reaction using radicals, and is easily available at a low cost, a photocurable material containing the sensitizer, a cured product of the photocurable material, and a material for a wiring harness containing the photocurable material. The curable sensitizer contains an alcohol (meth)acrylate synthesized from an alcohol having one or more hydroxy groups and two or more oxygen atoms in a molecule and a (meth) acrylate ingredient selected from a (meth)acrylic acid and a derivative thereof. An ester bond is formed between one of the hydroxy groups of the alcohol and the (meth)acrylate ingredient. The sensitizer is capable of increasing curability of a curable material when mixed in the material. The photocurable material contains the curable sensitizer and a photoinitiator. The material for the wiring harness contains the photocurable material.

Abstract: The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated with abnormal cell growth, for example, treating or preventing cancer or tumor growth, which methods include administering to a mammal in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

Abstract: A telescoping process for the preparation of 2-methoxymethyl-p-phenylenediamine, a cosmetically acceptable salt thereof, or mixture thereof. The process according to the present invention is a particularly cost effective process in that it avoids sophisticated chemical steps which requires special equipment or expensive catalysts and in that it comprises a recycling step of one of the starting materials, namely 2-methoxymethylaniline.

Abstract: This disclosure describes a low temperature process for the preparation of dimethyl amines from nitriles via reductive amination. In some embodiments, the process proceeds under mild conditions with aqeuous dimethylamine and show an unexpected rate acceleration by the inclusion of an acid addition salt of the dimethylamine.

Abstract: Proposed is a method of producing soluble silicates with organic cations at a given silicate modulus in the range of 1.5 to 20. The method consists of the reacting liquid suspension of a silica sol with the aqueous solution of a strong organic base. The silicate modulus is a molar ratio of SiO2:M2O, wherein M is an organic alkali cation. The aqueous solution of a strong organic base has a constant of base dissociation pKb equal to or greater than 4. If necessary, the soluble silicates with organic cations are obtained in a powdered form by evaporating the solution of the soluble silicates under vacuum below 4.2 kPa and at a temperature in the range of 20 to 30° C. and the product of evaporation are then dried by spraying.

Abstract: Objects of the present invention are to provide an industrially applicable method for producing an optically active ?-amino acid in high yield and in a highly enantioselective manner, to provide a simple production method of an optically active ?,?-disubstituted ?-amino acid, and to provide an intermediate useful for the above production methods of an optically active ?-amino acid and an optically active ?,?-disubstituted ?-amino acid. The present invention provides a production method of an optically active ?-amino acid or a salt thereof, the production method comprising introducing a substituent into the ? carbon in the ?-amino acid moiety of a metal complex represented by the following Formula (1): by an alkylation reaction, an aldol reaction, the Michael reaction, or the Mannich reaction, and releasing an optically pure ?-amino acid enantiomer or a salt thereof by acid decomposition of the metal complex.

Abstract: Alternative continuous downstream processes for the production of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

Abstract: The present disclosure relates, in general, to processes for converting 2,5-dichloroaniline compounds to the corresponding 2,5-dichlorobenzenediazonium compounds, and further relates to processes for the preparation of 2,5-dichlorophenol which is a key intermediate used in the manufacture of dicamba.

Abstract: The invention relates to a method for preparing isocyanates by phosgenating the corresponding amines, wherein low-boiling secondary components, excess phosgene, and the co-product hydrogen chloride are separated from the crude liquid isocyanate stream, which is obtained after the phosgenation has occurred, within a maximum of 60 minutes, and wherein the crude liquid isocyanate stream is not exposed to temperatures above 250° C. until said separation.

Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Abstract: The present invention relates to the use of fluorinated surfactants of formula (I) in pesticides.

Abstract: The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

Abstract: Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties. Also provided are methods of treatment and methods of preparation, as well as kits and unit dosages.

Abstract: The present invention is directed to novel pyrrolidine carboxylic acid derivatives, pharmaceutical compositions, and their use in treating and/or preventing metabolic diseases as agonists of g-protein coupled receptor 43.

Abstract: The present invention relates to 2,6-bis(aminomethyl)piperidine derivatives as such (in the following text abbreviated to “2,6-BAMP derivatives”) which are defined by the general formula (I) shown in the following text. In addition, the present invention relates to a process for preparing such 2,6-BAMP derivatives by hydrogenation of the corresponding 2,6-dicyanopiperidine derivatives (hereinafter abbreviated to “2,6-DCP derivatives”) in the presence of a catalyst. The present invention further provides for the use of the 2,6-BAMP derivatives of the invention as hardeners for epoxy resins, as intermediate in the preparation of diisocyanates, which play an important role in the production of polyurethanes, as starters in the preparation of polyetherols and/or as monomers for polyamide production. The present invention further relates to the diisocyanates as such prepared from the 2,6-BAMP derivatives and also the corresponding preparative process.

Abstract: The present invention relates to compounds and processes for preparing compounds of Formula (I), including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).

Abstract: Compounds of formula (I) wherein the other substituents HetAr, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in claim 1, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.

Abstract: The present invention provides a method of producing a 2-aminonicotinic acid benzyl ester derivative at a high yield and with a high purity. By reacting a benzyl halide derivative with a 2-aminonicotinic acid derivative in a polar solvent in the presence of a prescribed base, it is possible to obtain a 2-aminonicotinic acid benzyl ester derivative at a high yield and with a high purity.

Abstract: The present invention provides a method for synthesizing cationic bleach activators via a single-bath reaction, comprising steps of: separately dissolving 4-chloromethylbenoyl chloride and lactam in its respective solvent, adding an acid-binding agent to the lactam solution, next adding dropwisely 4-chloromethylbenoyl chloride solution into the lactam/acid binding-agent solution, and finally adding tertiary amine to the solution above to make a reaction solution, which is further treated with mixing and refluxing. The washed and dried final product is TBLC cationic bleach activator. The method of the present invention greatly simplifies the synthesizing process and lowers the stringency of reaction conditions for preparing cationic bleach activators (TBLC). At the same time, the present method produces TBLC cationic bleach activators with high yields, making it a suitable option for industrial production of these bleach activators.

Abstract: The present invention relates to pyrazole carboxamides derivatives of formula (1) wherein Y represents CR5 or N, T represents S or O, X1 and X2 represent a chlorine or a fluorine atom, and Z1 represents a substituted or non-substituted cyclopropyl; Their process of preparation, their use as fungicide, and/or anti-mycotoxin active agents, and/or insecticide, and/or nematicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

Abstract: Disclosed herein are embodiments of a compound capable of treating HIV. In particular disclosed embodiments, the compound is capable of inhibiting Nef, such as by acting as antagonists of HIV Nef function. Also disclosed are embodiments of a method of making the compound, embodiments of a method of using the compound, and embodiments of a method of identifying HIV Nef antagonists. The disclosed compound may be used alone or in combination with other pharmacologically active agents in order to promote reducing drug resistance and/or cumulative toxicity.

Abstract: The present invention relates to compounds of formula I having variables as described herein, which are useful for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

Abstract: The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

Abstract: An object of the present invention is to provide a novel method capable of producing rosuvastatin calcium and intermediates therefor efficiently, inexpensively and with high purity. The present invention provides a method of efficiently producing rosuvastatin calcium and intermediates therefor having a high purity at an industrial scale, without using an extremely low temperature reaction or a special asymmetric catalyst.

Abstract: Substituted uracil derivatives of formula (I), processes for their preparation, their use alone or in combinations for the treatment and/or prophylaxis of diseases, and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.

Abstract: The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.

Abstract: The invention provides compounds of formula I: and salts thereof wherein R1-R4 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts, and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: A process for preparing heonone (meth)acrylate by transesterification of alkyl (meth)acrylate with heonone.

Abstract: Analogs of PPAR5 and analogs of 20-OH-PGE2, which are PPAR5 agonists and 20-OH-PGE2 antagonists, respectively, and methods of using the same for inducing osteogenesis or chondrogenesis, are disclosed.

Abstract: The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.

Abstract: Cured epoxy resins are widespread because of their excellent mechanical and chemical properties. Typically, epoxy resins based on bisphenol A diglycidyl ethers or bisphenol F diglycidyl ethers are used, but these are problematic for many sectors because of their effect on the endocrine system. The present invention relates to glycidyl ethers of limonene-based diols and/or polyols, and to curable epoxy resin compositions based thereon as alternatives to the bisphenol A diglycidyl ethers or bisphenol F diglycidyl ethers, or the epoxy resin compositions based thereon.

Abstract: An object of the present invention is to provide high-purity gamma-butyrolactone (GBL) capable of preventing occurrence of reaction other than the object at the time of use, which reaction is caused due to a high acidity of GBL, and the present invention relates to a gamma-butyrolactone composition containing gamma-butyrolactone and a nitrogen-containing compound, wherein a content of the gamma-butyrolactone is 99.0% by mass or more, and a total content of the nitrogen-containing compound is 0.1 ppm by mass to 1,000 ppm by mass as converted to a nitrogen atom.

Abstract: The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to new anticancer agents based on miliusane compounds. The present invention also includes its preparation and application method for treating cancer.

Abstract: The present invention relates to a process for the preparation of 2-substituted 4-hydroxy-4-methyltetrahydropyrans.

Abstract: Described herein are ?9-THC prodrugs, methods of making ?9-THC prodrugs, formulations comprising ?9-THC prodrugs and methods of using ?9-THC. One embodiment described herein relates to the transdermal administration of a ?9-THC prodrug for treating and preventing diseases and/or disorders.

Abstract: The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.

Abstract: Provided are processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoin-dolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

Abstract: The present invention provides intermediates useful for the synthesis of Perampanel and processes employing said intermediates for preparing Perampanel. The invention also provides processes for making the intermediates, crystalline forms of the intermediates and the use of the crystalline forms for preparing Perampanel.

Abstract: This 2-pyridone compound represented by formula [1] or a tautomer of said compound, or a pharmaceutically acceptable salt of said compound or said tautomer, or a solvate of said compound or the like has a superior GK-activating effect and is useful as a pharmaceutical.

Abstract: The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein X1, X1?, X1?, R1, R2 and R3 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

Abstract: The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form in the treatment of hyperproliferative diseases in mammals, especially in humans.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, A, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, A, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.